We are working on a technology that would give women the opportunity to have children well into their forties and fifties, eliminate barriers for couples suffering from infertility, and potentially allow male-male couples to have biological children.
Long term, this technology could be a critical platform allowing for widespread genetic screening of embryos. If proven safe, it could even enable for genetic editing to eliminate and reduce the risk of devastating diseases for future generations – such as Alzheimer’s, heart disease and many different types of cancers.
This could become one of the most important technologies ever created.
We and others have shown that this technology works to make viable mouse eggs, and it can be used to make healthy, live mice. We are working on translating this technology to humans with the aim to make it a safe and accessible reproductive treatment.
We believe we have created a highly effective and open research environment, where everyone is united by the same goal. We are working on a difficult problem, and we are neither encumbered by limited resources, nor a need for individual team members to focus in isolation on their own projects for their own publications.
We think this type of research company serves as a model environment for how research should be done, and we invite you to come see for yourself.
Develop organoids to promote germ cell development. PhD or equivalent work experience with skills relevant to our work.
Help drive cell production and experiment analysis. qPCR and/or cell differentiation experience strongly desired.
1-2 year Fellowship for scientists with PhD or equivalent work experience to learn or deepen skills on how to work with iPSCs and organoids.
Analyze sequencing data to find unique, actionable insights into ovarian developmental biology.
Edit and engineer cells to generate specific phenotypes.